CARDIOVASCULAR JOURNAL OF AFRICA • SAHS Biennial Congress 16-18 September 2022 63 AFRICA Submission ID: 1384 Introduction Cardiovascular disease may adversely affect the incidence rate, severity of acute infection and post-covid period, and mortality rate associated with the new coronavirus infection. Methods An international registry ACTIV SARS-CoV-2 was established to evaluate the course of COVID-19 and involved experts from 7 countries (ClinicalTrials.gov: NCT04492384). The course of the acute period was assessed using data from 5808 patients. The course of post-covid period was assessed using the results of telephone calls to 2185 patients 3 months after recovery and to 1208 patients 6 months after recovery. Results 55.41% of the patients had arterial hypertension (AH) when they acquired the infection and were more likely to require in-hospital treatment (60.85% vs. 30.84% outpatients, p<0.001). AH in COVID-19 patients increased the mortality odds ratio both in the acute and the post-covid period. The mortality odds ratio was higher in patients over 60 and with multiple chronic comorbidities (Table 1). Table 1. Effects of AH on COVID-19 outcomes in the acute period and 3 months after recovery. Comorbidity types Surviving patients Lethal outcomes P Odds ratio (95% CI) Acute infection, hospitalized patients (n=4751) AH,% 59.88 82.33 <0.01 3.123 (2.324-4.198) AH+age over 60,% 38.78 70.57 <0.01 3.785 (2.946-4.862) AH+obesity,% 26.12 36.99 <0.01 1.661 (1.266–2.178) AH+IHD,% 18.86 43.50 <0.01 3.311 (2.532–4.33) AH+CHF,% 15.82 42.68 <0.01 3.963 (3.022–5.197) AH+CHF+IHD,% 10.74 32.93 <0.01 4.082 (3.054–5.455) AH+obesity+diabetes,% 9.1 17.89 <0.01 2.177 (1.535–3.086) AH+obesity+IHD,% 7.42 16.26 <0.01 2.421 (1.68–3.488) AH+CHF+IHD+obesity,% 3.98 13.82 <0.01 3.869 (2.578–5.806) AH+CHF+IHD+diabetes,% 3.55 13.41 <0.01 4.215 (2.784–6.382) AH+CHF+IHD+history of MI,% 3.65 10.16 <0.01 2.99 (1.896–4.716) 3 months after recovery (n=2185) AH,% 47.16 82.93 <0.01 5.442 (2.402-12.330) AH+age over 60,% 28.65 78.05 <0.01 8.857 (4.202-18.665) AH+IHD,% 2.41 9.76 0.003 4.373 (1.502-12.728) AH+CHF,% 7.28 31.71 <0.01 5.909 (3.000-11.640) AH+CHF+IHD,% 5.72 24.39 <0.01 5.313 (2.545-11.092) Increased BP over prior effective antihypertensive treatment was reported in 18.6% and 19.1% of patients in 3 and 6 months, respectively. Uncontrolled AH was the most common cause of medical care encounters (40.2% and 37.1%, respectively). AH accounted for 41.5% and 46.7% of the newly diagnosed conditions during 3- and 6-months follow-up, respectively. Conclusion AH increased hospitalization rate and negatively impacted the prognosis of the acute period in hospitalized COVID-19 patients and their prognosis during the first 3 months after recovery. The mortality risk increased in the patients over 60 and with several chronic conditions. AH was the most common newly diagnosed condition in the post-covid period. The presented data should be taken into account when planning prevention, treatment, and rehabilitation for COVID-19 patients. Name: Presenting Author Information Article Category Abstract Title “Eurasian Association of Internal Medicine”, Moscow, Russia agarutyunov@mail.ru English Abstract Clinical Significance of arterial hypertension in the acute infection and post-covid period based on the data from international ACTIV SARS-CoV-2 registry Author Affiliation: Email: Alexander G. Arutyunov POSTER PRESENTATION
RkJQdWJsaXNoZXIy NDIzNzc=